Wide Ranks

HALO

Halozyme Therapeutics, Inc.

48.47

Top Statistics
Market Cap 6 B Forward PE 10.35 Revenue Growth 34.30 %
Current Ratio 10.36 Trailing PE 16.05 Earnings Growth 72.10 %
Profit Margins 41.43 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 12.72 Enterprise / Revenue 7.43 Price To Sales Trailing12 Months 6.51
Profitability
Profit Margins 41.43 % Operating Margins 56.26 %
Balance Sheet
Total Cash 666 M Total Cash Per Share 5.24 Total Debt 1 B
Total Debt To Equity 339.05 Current Ratio 10.36 Book Value Per Share 3.56
All Measures
Short Ratio 662.00 % Message Board Id finmb_7931206 Fax 858 704 8311
Shares Short Prior Month 10 M Return On Equity 1.12 City San Diego
Uuid aa1169be-b80b-3480-8b26-f57e5230a087 Previous Close 47.79 First Trade Date Epoch Utc 1 B
Book Value 3.56 Beta 1.29 Total Debt 1 B
Volume 934507 Price To Book 13.62 Fifty Two Week Low 33.15
Total Cash Per Share 5.24 Total Revenue 947 M Shares Short Previous Month Date 1 B
Target Median Price 62.00 Max Age 86400 Recommendation Mean 2.20
Sand P52 Week Change 0.3133 Operating Margins 56.26 % Target Mean Price 62.44
Net Income To Common 392 M Short Percent Of Float 0.1111 Implied Shares Outstanding 136 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 3 M
Average Volume10days 3 M Total Cash 666 M Next Fiscal Year End 1 B
Revenue Per Share 7.43 Held Percent Insiders 0.0108 Ebitda Margins 58.37 %
Trailing PE 16.05 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 47.79 Target Low Price 50.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 53.72 Open 47.91 Free Cashflow 339 M
State CA Dividend Yield 0.00 % Return On Assets 0.1487
Time Zone Short Name EST Trailing Eps 3.02 Day Low 47.37
Address1 12390 El Camino Real Shares Outstanding 127 M Price Hint 2
Target High Price 75.00 Website https://halozyme.com 52 Week Change 0.2554
Average Volume 1 M Earnings Quarterly Growth 67.40 % Forward Eps 4.84
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 874.90 %
Is_sp_500 False Regular Market Day High 48.74 Profit Margins 41.43 %
Debt To Equity 339.05 Fifty Two Week High 65.53 Day High 48.74
Shares Short 10 M Regular Market Open 47.91 Industry Key biotechnology
Earnings Growth 72.10 % Enterprise To Revenue 7.43 Revenue Growth 34.30 %
Shares Percent Shares Out 0.0821 Operating Cashflow 402 M Currency USD
Time Zone Full Name America/New_York Market Cap 6 B Is_nasdaq_100 False
Zip 92130 Quote Type EQUITY Industry Biotechnology
Long Name Halozyme Therapeutics, Inc. Regular Market Day Low 47.37 Held Percent Institutions 1.00
Current Price 48.47 Enterprise To Ebitda 12.72 Financial Currency USD
Current Ratio 10.36 Gross Margins 73.65 % Industry Disp Biotechnology
Number Of Analyst Opinions 9 Country United States Float Shares 125 M
Two Hundred Day Average 49.48 Enterprise Value 7 B Price To Sales Trailing12 Months 6.51
Forward PE 10.35 Regular Market Volume 934507 Ebitda 552 M
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.

In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis.

Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.

Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.